GDD launches import "white list" for biomedical R&D items

Recently, Guangzhou Development District (GDD) and Huangpu district released the first batch of the import "white list" for biomedical research and development items and finalized the first batch "white list" containing three companies and nine imported items.

Companies listed in the "white list" are eligible to streamline customs clearance procedures by explicitly referencing included in the GDD import white list for biomedical research and development items when submitting relevant customs declaration forms within six months. This exemption obviates the requirement for the import drug customs clearance form, resulting in a time saving of approximately one month in customs clearance, enhancing procedural convenience.

Currently, GDD collectively accommodates over 4,700 biomedical enterprises, with over 130 large-scale enterprises, achieving an industrial output value of approximately 45.4 billion yuan ($6.27 billion) and a revenue scale exceeding 210 billion yuan, ranking at the forefront among all districts in Guangzhou.

As the first pilot area for the import "white list" system for biomedical research and development items in the province, GDD is committed to creating a high-quality business environment and promoting innovation in the biomedical industry.

In the following steps, GDD will continue to monitor the import progress of relevant items, strengthen supervision, and urge companies to standardize the use and management of "white list" items, ensuring that these items are solely used for research and development purposes.

Share - WeChat